Anagrelid

Číslo: 3 / 2010 (Obsah)
Rubrika: Profily léčiv
Obor: Hematoonkologie
Autoři: Prof. MUDr. Miroslav Penka, CSc.
Autoři - působiště: Oddělení klinické hematologie FN a LF MU, Brno
Citace: 1 Abe Andes W, Noveck RJ, Fleming JS. Inhibition of platelet production induced by an antiplatelet drug, anagrelid, in normal volunteers. Thromb Haemost 1984;52:325. 2 Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica 2004;89(2):215–32. 3 Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydoxyurea for patients with Essential Thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:113. 4 Doubek M, Brychtová Y, Doubek R, et al. Anagrelide in pregnancy: report of a case of essential thrombocythaemia. Ann Oncol 2004;83:726–7. 5 Elliott MA, Tefferi A. Interferon-alfa therapy in Polycythemia Vera and Essential Thrombocythemia. Semin Thromb Hemost 1997;23:463. 6 Gisslinger H, Kralovics R, Gotic M, et al. Non-Inferiority of Anagrelid Compared to Hydroxyurea in Newly Diagnose Patients with Essential Thrombocythemia. The ANAHYDRET- -Study. Blood 2007;110(11):1038A (abstract 3547). 7 Green A, Campbell P, Buck G, et al. The Medical Research Council PT1 Trial in Essentials Thrombocythemia. Blood 2004;104/11:5a–6a (abstract 6). 8 Harrison CN, Gale RE, Machin SK, et al. A large proportion of patients with a diagnosis of Essential Thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999;93:417–24. 9 Jaffe ES, Harris NL, Stein H, et al. World health organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001:352 . 10 Landolffi R, Rocca B, Patrono C. Bleeding and thrombosis in myeloproliferative disorders: mechanism and treatment. Crit Rev Oncol Hematol 1995;20:203–22. 11 Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in Polycythemia Vera. N Engl J Med 2004; 350:114–124. 12 Mesa RA, Tefferi A, Jacobsen SJ, et al. Population-based incidence and survival figures in Essential Thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County study. Am J Hematol 1999;61:10–15. 13 Michiels JJ, Kutti J, Stark P, et al. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis. Netherlands J Med 1999;54:46–62. 14 Michiels JJ, Barbui T, Finazzi G, et al. Diagnosis and treatment of Polycythemia vera possible future study design of the PVSG. Leuk Lymphoma 2000;36:239–53. 15 Michiels JJ, Thiele J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol 2002;76:133–45. 16 Murphy S, Peterson P, Iland H, et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997;34:29–39. 17 Penka M, Schwarz J, Pytlík R, et al. Doporučený postup diagnostiky a terapie esenciální trombocytemie a trombocytemie provázející myeloproliferativní onemocnění. Vnitř Lék 2005; 51(6):741–51. 18 Penka M, Schwarz J, Pavlík T, et al. Výsledky léčby nemocných s esenciální trombocytemií a dalšími myeloproliferacemi provázenými trombocytemií – zpráva z registru pacientů léčených Thromboreductinem. Vnitř Lék 2009;55/11:I–XII. 19 Penka M, Schwarz J, Pavlík T, et al. Esenciální trombocytemie a další myeloproliferace s trombocytemií v údajích registru pacientů léčených Thromboreductinem do konce roku 2007. Vnitř Lék 2008;54:775–82. 20 Petrides PE. Anagrelid: decade of clinical experiences with its use for the treatment of primary thrombocythaemia. Expert Opin Pharmacother 2004;5(8):1781–98. 21 Petrides PE, Beykirch MK, Trapp OM. Anagrelid, a novel platelet lowering option in Essential Thrombocythaemia: treatment experiences in 48 patients in Germany. Eur J Haematol 1998;61:71. 22 Petitt RM, Silverstein MN, Petrone ME. Anagrelid for controle of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 1997;34:51. 23 Pytlík R, Cmunt E, Kleibl Z, et al. Úloha anagrelidu v léčbě esenciální trombocytemie. Trans Hematol Dnes 2004;10(4): 154–60. 24 Silverstein MN, Tefferi A. Treatment of Essential Thrombocythemia with anagrelid. Semin Hematol 1999;36:23–5. 25 Solberg LA, Jr, Oles KJ, Tarach J, et al. The effects of anagrelid on human megakaryocytopoiesis. Blood 1989;6274(Suppl.1):20a. 26 Steurer M, Gastl G, Jedrzejczak W, et al. Anagrelid for Thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 2004;101(10):2239–46. 27 Storen EC, Tefferi A. Long-term use of anagrelid in young patients with Essential Thrombocythemia. Blood 2001;97: 836–66. 28 Thiele J, Kvasnicka HM, Diehl V, et al. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leuk Lymphoma 1999;33:207–18. 29 Thiele J, Kvasnicka HM, Graeff AS, et al. Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): A retrospective clinicopathological study of 120 patients. Am J Hematol 2002;70:283–91. 30 Thiele J, Kvasnicka HM, Zankovich R, et al. Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis. Ann Hematol 2001;80:160–5. 31 Tefferi A, Solberg LA, Silverstein MN. A clinical update on Polycythemia Vera and Essential Thrombocythemia. Am J Med 2000;109:141–9. 32 Tsimberidou MA, Colburn DE, Welch MA, et al. Anagrelid and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother Pharmacol 2003;52:229–34. 33 Weinfeld A, Swolin B, Westin J. Acute leukaemia after hydroxyurea therapy in Polycythaemia Vera and allied disorders: prospective study of efficacy and leukemogenicity with therapeutic implications. Eur J Haematol 1994;52:134–9. 34 Wright CA, Tefferi A. A single institutional experience with 43 pregnancies in Essential Thrombocythemia. Eur J Haematol 2001;66:152. 35 Schwarz J, Penka M, Doubek M, et al. JAK2 mutation and an additional thrombophilic state are major prothrombotic risk factors in myeloproliferations with thrombocythemia – data from a registry of anagrelid-treated patients. 13th Congress of the European Hematology Association, Kopenhagen, Denmark, June 12–15, 2008; Haematologica 2008;1:93 (abstract 0144), ISSN0390-6078. 36 Finazzi G, Barbui T. Risk-adapted therapy in essencial thrombocythemia and polycythemia vera. Review. Blood Rev 2005;19:243–52. 37 Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 2008; 93(11):1645–51. 38 Hoffman R, Prchal JT, Samuelson S, et al. Philadelphia Chromosom-Negative Myeloproliferative Disorders: Biology and Treatment. Biol Blood Marrow Transplant 2007;13:64–72. 39 Schwarz J, Pytlík R, Doubek M, et al. Analysis of risk factors: the rationale of the guidelines for diagnosis and treatment of Ph-negative myeloproliferative disorders with thrombocythemia of the Czech Hematological Society. Sem Thromb Haemost 2006;32(3):231–45.

Souhrn

Anagrelid je imidazochinazolinový derivát (6,7-dichlor-1,5-dihydroimidazol[2,1-b]-chinazolin-2(3)-1-monohydrochlorid monohydrát), který je možné využít k selektivní redukci zvýšeného počtu krevních destiček způsobeného vystupňováním destičkové krvetvorby.1,2 Způsobuje redukci velikosti a ploidity megakaryocytů v postmitotické fázi.10 Ve vyšších dávkách může mít i antiagregační účinky, jejichž podkladem je inhibice fosfodiesterázy.

Celý článek je dostupný jen pro předplatitele časopisu


Přihlášení

 

Předplatné

Více o předplatném

 
 
 
Jste odborný pracovník ve zdravotnictví?
Jsem odborníkem ve smyslu §2a Zákona č. 40/1995 Sb., o regulaci reklamy, ve znění pozdějších předpisů, čili jsem osobou oprávněnou předepisovat léčivé přípravky nebo osobou vydávat léčivé přípravky.

Potvrzuji, že jsem se seznámil/a s definicí odborník
dle zákona č. 40/1995 Sb.
Potvrzuji, že jsem se seznámil/a s riziky, jimž se jiná osoba než odborník vystavuje, vstoupí-li na stránky určené pro odborníky